Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma

Kevin D. Boyd1, Fiona M. Ross2, Laura Chiecchio2, GianPaolo Dagrada2, Zoe J. Konn2, William J. Tapper2, Brian A. Walker1, Christopher P. Wardell1, Walter M. Gregory3, Alex J. Szubert3, Faith E. Davies1, and Gareth J. Morgan1

Abstract

Background: Several cancer types have differences in incidence and clinical outcome dependent on gender, but these are not well described in myeloma. The aim of this study was to characterize gender disparities in myeloma.

Methods: We investigated the association of gender with the prevalence of tumor genetic lesions and the clinical outcome of 1,960 patients enrolled in the phase III clinical trial MRC Myeloma IX. Genetic lesions were characterized by FISH.

Results: Disparities were found in the prevalence of primary genetic lesions with immunoglobulin heavy chain gene (IGH) translocations being more common in women (50% of female patients vs. 38% of male patients, \(P < 0.001\)) and hyperdiploidy being more common in men (50% female vs. 62% male, \(P < 0.001\)). There were also differences in secondary genetic events with del(13q) (52% female vs. 41% male, \(P < 0.001\)) and +1q (43% female vs. 36% male, \(P = 0.042\)) being found more frequently in female myeloma patients. Female gender was associated with inferior overall survival (median: 44.8 months female vs. 49.9 months male, \(P = 0.020\)).

Conclusions: We found gender-dependent differences in the prevalence of the primary genetic events of myeloma, with IGH translocations being more common in women and hyperdiploidy more common in men. This genetic background may impact subsequent genetic events such as +1q and del(13q), which were both more frequent in women. The higher prevalence of lesions associated with poor prognosis in the female myeloma population, such as t(4;14), t(14;16) and +1q, may adversely affect clinical outcome.

Impact: These differences suggest that gender influences the primary genetic events of myeloma. Cancer Epidemiol Biomarkers Prev; 20(8); 1703–7. ©2011 AACR.

Introduction

Several cancer types have differences in incidence and clinical outcome dependent on gender (1). Lung cancer, for example, is more common in men, and women with lung cancer have better survival than men (2). Moreover, a sex-specific tumor genomic profile has been described in lung cancer, strongly suggesting that there is a gender-specific phenotype (2, 3). These data suggest that gender can influence the etiology and natural history of some malignancies.

In myeloma, the primary genetic lesions that give rise to a clonal plasma cell population are hyperdiploidy and immunoglobulin heavy chain gene (IGH) translocations (4). Hyperdiploidy in myeloma is characterized by gain of multiple odd numbered chromosomes, and the events giving rise to this abnormality are not well understood. IGH translocations arise following aberrant class switch recombination events during B-cell differentiation and feature reciprocal translocation of the IGH allele at 14q32, usually with one of 5 partner oncogenes (FGFR3, CCND1, CCND3, MAF, or MAFB; refs. 5, 6). These two etiologic pathways have been used to classify myeloma patients into a hyperdiploid group and non-hyperdiploid group characterized by a high rate of IGH translocations (5, 7). These early genetic events give rise to a clonal plasma cell population, with further events such as structural chromosomal abnormalities, mutation, and epigenetic changes required for progression to malignancy (8–10).

It is unknown why these pathogenic events occur in certain individuals but evidence of genetic susceptibility
is suggested by an increased incidence of myeloma in first-degree relatives of myeloma patients, within some family groups, and in certain racial groups. Several large population-based studies have found that first-degree relatives of subjects with myeloma or monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of developing a plasma cell dyscrasia (11–13). Further evidence of hereditable susceptibility is provided by familial clusters of MGUS and myeloma (14–16). Racial background has been shown to be important, with myeloma being twice as common in African Americans as white Americans and least common in Americans of Asian origin (17). The premalignant condition that precedes myeloma, MGUS, has a similar pattern, suggesting that the higher rate of myeloma in African Americans is due to different rates of primary genetic events as opposed to secondary progression events (18, 19).

Gender could also exert similar effects. We have investigated the relationship of gender to the risk of developing myeloma, the prevalence of tumor genetic lesions, and the clinical outcome of patients enrolled in the MRC Myeloma IX trial.

Methods

Patients

Patients \( (N = 1,960) \) were enrolled in the MRC Myeloma IX phase III clinical trial (ISRCTN68454111; MREC/02/8/98), the design and results of which are described elsewhere (20). Patients over the age of 18 years newly diagnosed with symptomatic myeloma requiring treatment were eligible for selection. Exclusion criteria were diagnosed with symptomatic myeloma requiring treatment with the difference between the curves analyzed using the log-rank test. Multivariate analysis was conducted using the proportional hazards regression model of Cox. All \( P \) values were 2-sided, and values of \( P < 0.05 \) were taken as significant.

Results/Discussion

Of the 1,960 patients enrolled in the trial, 1,165 (59.4%) were male and 795 (40.6%) were female. These figures are consistent with population-based statistics, with incidence rates of 4.4 per 100,000 in men and 2.9 per 100,000 in women equating to a 60:40 split (17). There were few significant differences in baseline clinical and laboratory variables (Supplementary Table S1). The median age of female trial patients was 2 years older than for men (64 years male vs. 66 years female, \( P = 0.007 \)) and female patients were associated with higher levels of serum lactate dehydrogenase, which have been linked to adverse prognosis (median: 320 U/L male vs. 345 U/L female, \( P < 0.001; \) ref. 23).

The different incidence of myeloma in men and women suggests that gender may influence etiologic events. In this context, we found differences in the rates of primary pathogenetic lesions dependent on gender (Table 1). \( IGH \) translocations were more common in women (50.1% of female patients vs. 37.9% of male patients, \( P < 0.001 \)). When the \( IGH \) translocations were examined on the basis of the 5 common partner genes, all groups were found at higher frequencies in female patients, with the most significant differences seen in the \( t(4;14) \) group (14.7% of female patients vs. 9.3% of male patients, \( P = 0.009 \)) and the \( t(14;16) \) group (5.7% of female patients vs. 1.6% of male, \( P < 0.001 \)). Conversely, hyperdiploidy was more common in men than women (49.7% of female patients vs. 61.7% of male patients, \( P < 0.001 \)).

A range of chromosomal regional deletions and gains were examined and both del(13q) and +1q were found to be more frequent in female patients [del(13q): 52.3% of female patients vs. 40.6% of male patients, \( P < 0.001; +1q: 43.1\% \) of female patients vs. 36.2% of male patients, \( P = 0.042 \)]. Both these lesions showed a significant positive association with \( IGH \) translocations in the overall data set and were negatively associated with hyperdiploidy so it is likely that their increased frequency in female patients was a secondary consequence of the underlying rates of hyperdiploidy and \( IGH \) translocations. No gender differences were seen in the prevalence of del(1p), del(16q), del (17p), or del(22q), and there were no differences in the percentage of men and women with abnormal karyotypes by conventional cytogenetics (Table 1).

Survival differences were observed when comparing the sexes, with female gender being associated with impaired OS (median OS: 44.8 months female vs. 49.9 months male, \( P = 0.020; \) Fig. 1; Supplementary Table S2). There was also a trend toward impaired PFS for women that did not reach a level of significance (median: 16.0 months female vs. 19.9 months male, \( P = 0.105 \)). The association of gender with OS was not significant in the log-rank test. Multivariate analysis was conducted using the proportional hazards regression model of Cox. All \( P \) values were 2-sided, and values of \( P < 0.05 \) were taken as significant.

Results/Discussion

Of the 1,960 patients enrolled in the trial, 1,165 (59.4%) were male and 795 (40.6%) were female. These figures are consistent with population-based statistics, with incidence rates of 4.4 per 100,000 in men and 2.9 per 100,000 in women equating to a 60:40 split (17). There were few significant differences in baseline clinical and laboratory variables (Supplementary Table S1). The median age of female trial patients was 2 years older than for men (64 years male vs. 66 years female, \( P = 0.007 \)) and female patients were associated with higher levels of serum lactate dehydrogenase, which have been linked to adverse prognosis (median: 320 U/L male vs. 345 U/L female, \( P < 0.001; \) ref. 23).

The different incidence of myeloma in men and women suggests that gender may influence etiologic events. In this context, we found differences in the rates of primary pathogenetic lesions dependent on gender (Table 1). \( IGH \) translocations were more common in women (50.1% of female patients vs. 37.9% of male patients, \( P < 0.001 \)). When the \( IGH \) translocations were examined on the basis of the 5 common partner genes, all groups were found at higher frequencies in female patients, with the most significant differences seen in the \( t(4;14) \) group (14.7% of female patients vs. 9.3% of male patients, \( P = 0.009 \)) and the \( t(14;16) \) group (5.7% of female patients vs. 1.6% of male, \( P < 0.001 \)). Conversely, hyperdiploidy was more common in men than women (49.7% of female patients vs. 61.7% of male patients, \( P < 0.001 \)).

A range of chromosomal regional deletions and gains were examined and both del(13q) and +1q were found to be more frequent in female patients [del(13q): 52.3% of female patients vs. 40.6% of male patients, \( P < 0.001; +1q: 43.1\% \) of female patients vs. 36.2% of male patients, \( P = 0.042 \)]. Both these lesions showed a significant positive association with \( IGH \) translocations in the overall data set and were negatively associated with hyperdiploidy so it is likely that their increased frequency in female patients was a secondary consequence of the underlying rates of hyperdiploidy and \( IGH \) translocations. No gender differences were seen in the prevalence of del(1p), del(16q), del (17p), or del(22q), and there were no differences in the percentage of men and women with abnormal karyotypes by conventional cytogenetics (Table 1).

Survival differences were observed when comparing the sexes, with female gender being associated with impaired OS (median OS: 44.8 months female vs. 49.9 months male, \( P = 0.020; \) Fig. 1; Supplementary Table S2). There was also a trend toward impaired PFS for women that did not reach a level of significance (median: 16.0 months female vs. 19.9 months male, \( P = 0.105 \)). The association of gender with OS was not significant in the log-rank test. Multivariate analysis was conducted using the proportional hazards regression model of Cox. All \( P \) values were 2-sided, and values of \( P < 0.05 \) were taken as significant.
multivariate analysis, suggesting that competing variables were involved (Supplementary Table S3). Age may play a small role, as the median age of women in the trial was 2 years older than men, and when age adjusted, the association of female gender with impaired survival becomes less significant ($P = 0.079$). However, more significant is the fact that the genetic lesions that were more common in women [t(4;14), t(14;16), del(13q), and $+1q$] were all strongly associated with impaired survival in univariate analysis, with t(4;14), t(14;16), and $+1q$ being associated with short survival in multivariate testing (Supplementary Table S3). In bivariate analysis with any of these lesions, gender ceases to be significantly associated with OS, so the genetic background of male and female patients is likely to play an important role in the observed survival differences. Overall, we think that the moderate impairment in survival associated with female gender mainly reflects the increased prevalence of adverse genetic lesions in female myeloma patients.

A caveat of any clinical trial study, when compared with a population-based study, is that trial selection criteria may introduce bias that affects the generalizability of findings to the overall population. In comparison with many clinical trials, the inclusion and exclusion criteria of the MRC Myeloma IX trial were not strict so that trial participants were representative of the general myeloma population. Unusually, it was a trial designed for myeloma patients of all ages, with the age range of enrolled patients being 31 to 89 years, with a median age of 65 years. This is slightly lower than the median age at diagnosis reported in population statistics (69 years), perhaps reflecting a reluctance of clinicians to enter older, frailer patients into clinical trials (17). To address this possible bias, we specifically examined the prevalence of genetic abnormalities in patients aged 70 years or over ($n = 380$). This subgroup analysis corroborated the original findings, with IGH translocations being more common in older female patients (48.6% of female patients vs. 34.6% of male patients, $P = 0.013$) and hyperdiploidy being more frequent in older male patients (30.4% of female patients vs. 65.6% of male patients, $P = 0.008$). The gender mix of the trial patients was identical to population data, suggesting that gender selection was unbiased. About 97% of patients were Caucasian, so these findings require validation in other ethnic groups.

### Table 1. A comparison of the incidence of tumor genetic lesions detected by FISH in male and female patients

<table>
<thead>
<tr>
<th>Variable</th>
<th>Male</th>
<th>Female</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes, $n$</td>
<td>No, $n$</td>
<td>% positive</td>
</tr>
<tr>
<td>Abnormal karyotype</td>
<td>129</td>
<td>252</td>
<td>33.9</td>
</tr>
<tr>
<td>Hyperdiploidy</td>
<td>384</td>
<td>238</td>
<td>61.7</td>
</tr>
<tr>
<td>Any IGH translocation</td>
<td>239</td>
<td>392</td>
<td>37.9</td>
</tr>
<tr>
<td>t(4;14)</td>
<td>60</td>
<td>585</td>
<td>9.3</td>
</tr>
<tr>
<td>t(6;14)</td>
<td>4</td>
<td>629</td>
<td>0.6</td>
</tr>
<tr>
<td>t(11;14)</td>
<td>81</td>
<td>564</td>
<td>12.6</td>
</tr>
<tr>
<td>t(14;16)</td>
<td>10</td>
<td>634</td>
<td>1.6</td>
</tr>
<tr>
<td>t(14;20)</td>
<td>9</td>
<td>631</td>
<td>1.4</td>
</tr>
<tr>
<td>del(1p)</td>
<td>53</td>
<td>479</td>
<td>10.0</td>
</tr>
<tr>
<td>del(13q)</td>
<td>256</td>
<td>375</td>
<td>40.6</td>
</tr>
<tr>
<td>del(16q)</td>
<td>102</td>
<td>465</td>
<td>18.0</td>
</tr>
<tr>
<td>del(17p)</td>
<td>55</td>
<td>563</td>
<td>8.9</td>
</tr>
<tr>
<td>del(22q)</td>
<td>62</td>
<td>440</td>
<td>12.4</td>
</tr>
<tr>
<td>$+1q$</td>
<td>200</td>
<td>352</td>
<td>36.2</td>
</tr>
</tbody>
</table>

Figure 1. Overall survival of male and female patients in the Myeloma IX trial. Female median OS was 44.8 months compared with 49.9 months for males.
In summary, we found gender-dependent differences in the prevalence of *IGH* translocations and hyperdiploidy in newly presenting myeloma patients, with *IGH* translocations being more common in women and hyperdiploidy more common in men. This genetic background may impact subsequent genetic events such as +1q and del(13q), which were both more frequent in women. The relevance of these findings is that it helps to explain the observed gender-dependent survival differences, with female gender being associated with impaired survival due to the increased frequency of genetic lesions associated with poor clinical outcome, especially t(4;14), t(14;16), and +1q. Moreover, it also implies that gender may influence the etiologic events of myeloma. Women have a lower risk of developing myeloma and are more likely to develop myeloma as a result of aberrant class switch recombination events. Conversely, men have a higher risk of developing myeloma and are more likely to develop myeloma as a result of hyperdiploidy. Although a genetic basis for myeloma risk has been suggested to be due to variation in genes associated with innate immunity or cell cycle, these have not been reported to be different in men and women (24, 25). It is possible that *IGH* translocations or hyperdiploidy may in some way be influenced by variation in genes situated on the sex chromosomes, or by hormonal differences between men and women, and this should be a focus for further study.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

The authors thank Rebecca Protheroe, David Stockley, Tim Parker, Hazel Robinson, Elisabet Dachs Cabanas, and Christina Rudduck of the LLR UKMF Cytogenetics group for probe preparation and FISH scoring. They also thank staff from the Clinical Trials Research Unit, University of Leeds, for trial coordination and data management. The study was supported by the National Institute for Health Research, through the National Cancer Research Network.

**Grant Support**

Main financial support for the Myeloma IX clinical trial was from UK Medical Research Council, with additional funding in the form of unrestricted educational grants from Novartis, Schering Health Care, Chugai, Pharmion, Celgene, and Ortho Biotech. The LLR UKMF Cytogenetics group received financial support from Leukaemia and Lymphoma Research. The Institute of Cancer Research received support from Cancer Research UK, Myeloma UK, and the Biological Research Center of the National Institute for Health Research at the Royal Marsden Hospital.

Received February 9, 2011; revised May 18, 2011; accepted June 2, 2011; published OnlineFirst June 15, 2011.
cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006;20:1610–7.


Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma

Kevin D. Boyd, Fiona M. Ross, Laura Chiecchio, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1055-9965.EPI-11-0157

Supplementary Material
Access the most recent supplemental material at:
http://cebp.aacrjournals.org/content/suppl/2011/06/13/1055-9965.EPI-11-0157.DC1

Cited articles
This article cites 24 articles, 13 of which you can access for free at:
http://cebp.aacrjournals.org/content/20/8/1703.full.html#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
/content/20/8/1703.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.